At AAN 2025, three posters presented the sustained long-term efficacy and real-world impact of Lundbeck’s Vyepti for migraine ...

W hen it comes to treating a chronic condition like migraine, Western medicine is the new kid on the block, relatively speaking. After all, the vast majority of today’s pharmace ...

Gepants are a type of anti-CGRP drug that may be effective in treating menstrual migraine attacks. They’re safe to use if you have a history of heart attack or stroke, but they may interact with ...

there is fierce competition with several oral CGRP drugs or 'gepants' on the market including AbbVie's Ubrelvy (ubrogepant) for treatment and Qulipta (atogepant) for prevention, which collectively ...

There are two types of CGRP medications: monoclonal antibodies and small-molecule antagonists (gepants). Both can be used to limit how often migraines occur, and how severe and how long the symptoms ...

Vyepti was approved by the FDA for the prevention of migraine in adults in 2020. As the last of the anti-CGRP mAbs to enter the migraine market, Vyepti has seen moderate uptake since its approval ...

SAN DIEGO -- Fremanezumab (Ajovy) cut monthly migraine days in children and adolescents with episodic migraine, according to the SPACE trial. The phase III study showed a reduction in monthly ...

Key opinion leaders (KOLs) previously interviewed by GlobalData had noted that the gepants had similar efficacy to the triptans and as such, favourable patient opinions of gepants could increase ...

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing ...

If approved, AJOVY would be the only calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, helping to address ...